ArticleFrontiers in microbiology2024
Urinary tract infections in older adults: associated factors for extended-spectrum beta-lactamase production.
Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Increased Prevalence of Multidrug-ResistantLife (Basel, Switzerland) · 2026Article
- Distribution of Uropathogens and Molecular Characterisation of Virulence Genes of UropathogenicPathogens (Basel, Switzerland) · 2026Article
- A DWI histogram-based nomogram for preoperative prediction of pathogens and antibiotic resistance in perianal abscesses.International journal of colorectal disease · 2026Article
- Etiopathogenesis and Antibacterial Therapy Approach in Patients with Acute Obstructive Pyelonephritis-A Retrospective Study.Antibiotics (Basel, Switzerland) · 2026Article
- Risk Stratification for ESBL-Producing Enterobacterales in Elderly Diabetic Patients with Urinary Tract Infections: A Multicenter Model to Support Empirical Antibiotic Decision-Making.Infection and drug resistance · 2026Article
- Recurrent Urinary Tract Infection Caused by Multidrug-ResistantCase reports in infectious diseases · 2026Article
- Prevalence of Urinary Tract Infections Caused by Extended-Spectrum β-LactamaseInfection and drug resistance · 2026Article
- Retrospective study on antibiotic resistance profiles of uropathogenicFrontiers in microbiology · 2026Article
- Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.BMC infectious diseases · 2025Article
- Cefixime-clavulanic acid in ESBL-producing E. coli lower urinary tract infections: a 13-patient case series.BMC infectious diseases · 2025Article
- Risk Factors and Clinical Impact of Extended-Spectrum Beta-Lactamase (ESBL)-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Prevalence, Risk Factors and Antibiotic Resistance of Extended-Spectrum Beta-Lactamase-ProducingChildren (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL) producing Materials and methods: This was a prospective observational study. Hospitalized patients of age > 65 with community-onset or hospital-acquired upper UTI due to Results: A total of 97 patients were included. ESBL prevalence among UTIs with Conclusion: Severe UTI in older men with a history of recurrent UTI may be a warning to the clinician for ESBL production in the setting of high ESBL prevalence. Carbapenems may be prioritized in the empirical treatment of patients with known risk factors for ESBL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.